Renee
4 years ago
Companies that have been suspended under "questions" must answer all of the SEC's 'questions' and must prove to the SEC that no frauds or securities violations occurred that caused the SEC to suspend the stock.
Of the over 3,600 SEC Suspensions over the last 11 years only a few companies have ever successfully satisfied all of the SEC's questions to regain quotations. Most companies don't ever bother to answer the SEC's questions because the SEC only suspends a stock when they have incontrovertible evidence that securities violations occurred that no company can satisfy or justify to the SEC.
Excerpt from BMGP's SEC Suspension Order:
BMGP SEC Suspension "because of questions regarding: the adequacy and accuracy of information concerning the securities of each of the issuers listed above because questions have arisen as to their operating status, if any; the recent, increased activity and volatility in trading in the securities of each of these issuers, in the absence of any publicly available news or recent information by these issuers; and certain social media accounts may have been or may be engaged in a coordinated attempt to artificially influence their share prices. The stock of each of the issuers above is quoted and traded on OTC Link whose parent company is OTC Markets Group, Inc. None of the issuers above has posted any information with OTC Markets Group, Inc. or filed any information with the Securities and Exchange Commission for at least nine months."
https://www.sec.gov/litigation/suspensions/2021/34-91296.pdf
Order:
https://www.sec.gov/litigation/suspensions/2021/34-91296-o.pdf
Renee
4 years ago
BMGP SEC Suspension "because of questions regarding: the adequacy and accuracy of information concerning the securities of each of the issuers listed above because questions have arisen as to their operating status, if any; the recent, increased activity and volatility in trading in the securities of each of these issuers, in the absence of any publicly available news or recent information by these issuers; and certain social media accounts may have been or may be engaged in a coordinated attempt to artificially influence their share prices. The stock of each of the issuers above is quoted and traded on OTC Link whose parent company is OTC Markets Group, Inc. None of the issuers above has posted any information with OTC Markets Group, Inc. or filed any information with the Securities and Exchange Commission for at least nine months."
https://www.sec.gov/litigation/suspensions/2021/34-91296.pdf
Order:
https://www.sec.gov/litigation/suspensions/2021/34-91296-o.pdf
magicmikeeg
4 years ago
Have to rely on other places for PR!
Clinical trials for testing in 20-21 BMGP!! News
Parasitology and Mycology Rapid Tests and POC - Medical Devices Pipeline Assessment, 2020
Summary
The Medical Devices sector report, โParasitology and Mycology Rapid Tests and POC - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Parasitology & Mycology Rapid Tests & POC pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Parasitology & Mycology Rapid Tests & POC comprises of rapid test kits intended for rapid diagnosis, with immediate results, through immuno assays for the detection of pathogenic protozoans and fungi.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Parasitology & Mycology Rapid Tests & POC under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Parasitology & Mycology Rapid Tests & POC and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment/industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of Parasitology & Mycology Rapid Tests & POC under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the productโs current stage of development, territory and estimated launch date